OncoMatch

OncoMatch/Clinical Trials/NCT06397235

DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC

Is NCT06397235 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including DEB-TACE+HAIC and DEB-TACE for hepatocellular carcinoma non-resectable.

Phase 2RecruitingSecond Affiliated Hospital of Guangzhou Medical UniversityNCT06397235Data as of Jun 2026Location: China

Treatment: DEB-TACE+HAIC · DEB-TACEThis study is conducted to evaluate the efficacy and safety of transarterial chemoembolization with drug-eluting beads (DEB-TACE) combined with hepatic artery infusion chemotherapy (HAIC) with oxaliplatin and raltitrexed (RALOX-HAIC) versus DEB-TACE alone for unresectable large hepatocellular carcinoma (HCC).

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

DEB-TACE+HAICDEB-TACE

Cancer type

Hepatocellular Carcinoma

Performance status

ECOG 0–1(Restricted strenuous activity)

Demographics

Ages ≤ 75

Prior therapy

Cannot have received: palliative treatment (TACE, transcatheter arterial embolization, HAIC, radiation therapy, systemic therapy)

Previous palliative treatments, including TACE, transcatheter arterial embolization, HAIC, radiation therapy, systemic therapy

Lab requirements

Blood counts

platelet count ≥75×10^9/L, leukocyte >3.0×10^9/L, Neutrophil count ≥1.5×10^9/L

Kidney function

creatinine clearance≤1.5×ULN

Liver function

Child-Pugh score 5-7; ASL and AST≤5×ULN; prolongation of prothrombin time ≤4 seconds

Adequate organ and hematologic function with platelet count ≥75×10^9/L, leukocyte >3.0×10^9/L, Neutrophil count ≥1.5×10^9/L, ASL and AST≤5×ULN, creatinine clearance≤1.5×ULN, and prolongation of prothrombin time ≤4 seconds

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06397235 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior palliative treatment disqualifies patients from enrollment.

Is there an age limit?

Yes. Patients must be 75 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify